TY - JOUR
T1 - Onset of androgen deprivation therapy leads to rapid deterioration of body composition, physical performance, cardiometabolic health and quality-of-life in prostate cancer patients
AU - Overkamp, M.
AU - Houben, L.H.P.
AU - van der Meer, S.
AU - van Roermund, J.G.H.
AU - Bos, R.
AU - Kokshoorn, A.P.J.
AU - Larsen, M.S.
AU - van Loon, L.J.C.
AU - Beelen, M.
AU - Beijer, S.
N1 - Funding Information:
M.S. Larsen is an employee of Arla Foods Ingredients Group. L. J. C. van Loon has received research grants, consulting fees, speaking honoraria, or a combination of these for research on the impact of exercise and nutrition on muscle metabolism, which include funding from companies such as Friesland Campina and Arla Foods Ingredients Group. A full overview on research funding is provided at: https://www.maastrichtuniversity.nl/l.vanloon . M. Beelen has received a research grant from Arla Foods Ingredients Group. S. Beijer has received a research grant, consulting fees, speaking honoraria, or a combination of these from Baxter, Nutricia, and Arla Foods Ingredients Group. All other authors declare no competing interests.
Funding Information:
This project was organized by and executed under the auspices of TiFN (Wageningen, The Netherlands), a public–private partnership on precompetitive research in food and nutrition (Project code: 16NH03). Funding for this research was obtained from KWF Kankerbestrijding (Amsterdam, The Netherlands) and Arla Foods Ingredients (Viby J, Denmark). The researchers are responsible for the study design, data collection and analyses, decision to publish and preparation of the manuscript. The industrial partner has contributed to the project through regular discussion and was involved in the study design. The authors greatly appreciate all patients who volunteered to participate in the study. We thank the staff of the urologic departments of the participating hospitals, the department of physiotherapy of JBZ, and the Sports Medical Center of JBZ for their collaboration and assistance. Also, we thank the staff of the radiology departments of the participating hospitals.
Publisher Copyright:
© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023/11/2
Y1 - 2023/11/2
N2 - ObjectivesTo assess the adverse impact of the first 5 months of androgen deprivation therapy on body composition, physical performance, cardiometabolic health and health-related quality-of-life in prostate cancer patients.Materials and MethodsThirty-four prostate cancer patients (70 +/- 7 years) were assessed shortly after initiation of androgen deprivation therapy and again 5 months thereafter. Measurements consisted of whole-body dual-energy x-ray absorptiometry (body composition), computed tomography scanning of the upper leg (muscle mass), one-repetition maximum leg press (muscle strength), cardiopulmonary exercise testing (aerobic capacity), blood draws (metabolic parameters), accelerometry (habitual physical activity) and questionnaires (health-related quality-of-life). Data were analyzed with Student's paired t-tests.ResultsOver time, whole-body fat mass (from 26.2 +/- 7.7 to 28.4 +/- 8.3 kg, p < 0.001) and fasting insulin (from 9.5 +/- 5.8 to 11.3 +/- 6.9 mU/L, p < 0.001) increased. Declines were observed for quadriceps cross-sectional area (from 66.3 +/- 9.1 to 65.0 +/- 8.5 cm(2), p < 0.01), one-repetition maximum leg press (from 107 +/- 27 to 100 +/- 27 kg, p < 0.01), peak oxygen uptake (from 23.2 +/- 3.7 to 20.3 +/- 3.4 mL/min/kg body weight, p < 0.001), step count (from 7,048 +/- 2,277 to 5,842 +/- 1,749 steps/day, p < 0.01) and health-related quality-of-life (from 84.6 +/- 13.5 to 77.0 +/- 14.6, p < 0.001).ConclusionsAndrogen deprivation therapy induces adverse changes in body composition, muscle strength, cardiometabolic health and health-related quality-of-life already within 5 months after the start of treatment, possibly largely contributed by diminished habitual physical activity. Prostate cancer patients should, therefore, be stimulated to increase their habitual physical activity immediately after initiation of androgen deprivation therapy, to limit adverse side-effects and to improve health-related quality-of-life.
AB - ObjectivesTo assess the adverse impact of the first 5 months of androgen deprivation therapy on body composition, physical performance, cardiometabolic health and health-related quality-of-life in prostate cancer patients.Materials and MethodsThirty-four prostate cancer patients (70 +/- 7 years) were assessed shortly after initiation of androgen deprivation therapy and again 5 months thereafter. Measurements consisted of whole-body dual-energy x-ray absorptiometry (body composition), computed tomography scanning of the upper leg (muscle mass), one-repetition maximum leg press (muscle strength), cardiopulmonary exercise testing (aerobic capacity), blood draws (metabolic parameters), accelerometry (habitual physical activity) and questionnaires (health-related quality-of-life). Data were analyzed with Student's paired t-tests.ResultsOver time, whole-body fat mass (from 26.2 +/- 7.7 to 28.4 +/- 8.3 kg, p < 0.001) and fasting insulin (from 9.5 +/- 5.8 to 11.3 +/- 6.9 mU/L, p < 0.001) increased. Declines were observed for quadriceps cross-sectional area (from 66.3 +/- 9.1 to 65.0 +/- 8.5 cm(2), p < 0.01), one-repetition maximum leg press (from 107 +/- 27 to 100 +/- 27 kg, p < 0.01), peak oxygen uptake (from 23.2 +/- 3.7 to 20.3 +/- 3.4 mL/min/kg body weight, p < 0.001), step count (from 7,048 +/- 2,277 to 5,842 +/- 1,749 steps/day, p < 0.01) and health-related quality-of-life (from 84.6 +/- 13.5 to 77.0 +/- 14.6, p < 0.001).ConclusionsAndrogen deprivation therapy induces adverse changes in body composition, muscle strength, cardiometabolic health and health-related quality-of-life already within 5 months after the start of treatment, possibly largely contributed by diminished habitual physical activity. Prostate cancer patients should, therefore, be stimulated to increase their habitual physical activity immediately after initiation of androgen deprivation therapy, to limit adverse side-effects and to improve health-related quality-of-life.
KW - adipose tissue
KW - fatigue
KW - habitual physical activity
KW - muscle mass
KW - muscle strength
KW - MEN
KW - STRENGTH
KW - QUESTIONNAIRE
KW - INSTRUMENT
KW - FATIGUE
U2 - 10.1080/21681805.2023.2168050
DO - 10.1080/21681805.2023.2168050
M3 - Article
C2 - 36703515
SN - 2168-1805
VL - 57
SP - 60
EP - 66
JO - Scandinavian Journal of Urology
JF - Scandinavian Journal of Urology
IS - 1-6
ER -